Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015-17.

Bin Lu, Liu H, Tabor DE, Tovchigrechko A, Qi Y, Ruzin A, Esser MT, Jin H.

Sci Rep. 2019 Mar 7;9(1):3898. doi: 10.1038/s41598-019-40387-y.

2.

Comparison of GeneXpert MRSA/SA ETA assay with semi-quantitative and quantitative cultures and nuc gene-based qPCR for detection of Staphylococcus aureus in endotracheal aspirate samples.

Coppens J, Van Heirstraeten L, Ruzin A, Yu L, Timbermont L, Lammens C, Matheeussen V, McCarthy M, Jorens P, Ieven M, Kumar-Singh S, Goossens H, Malhotra-Kumar S.

Antimicrob Resist Infect Control. 2019 Jan 5;8:4. doi: 10.1186/s13756-018-0460-8. eCollection 2019.

3.

Interplay of Klebsiella pneumoniae fabZ and lpxC Mutations Leads to LpxC Inhibitor-Dependent Growth Resulting from Loss of Membrane Homeostasis.

Mostafavi M, Wang L, Xie L, Takeoka KT, Richie DL, Casey F, Ruzin A, Sawyer WS, Rath CM, Wei JR, Dean CR.

mSphere. 2018 Oct 31;3(5). pii: e00508-18. doi: 10.1128/mSphere.00508-18.

4.

Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae.

Dean CR, Barkan DT, Bermingham A, Blais J, Casey F, Casarez A, Colvin R, Fuller J, Jones AK, Li C, Lopez S, Metzger LE 4th, Mostafavi M, Prathapam R, Rasper D, Reck F, Ruzin A, Shaul J, Shen X, Simmons RL, Skewes-Cox P, Takeoka KT, Tamrakar P, Uehara T, Wei JR.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01200-18. doi: 10.1128/AAC.01200-18. Print 2018 Oct.

5.

Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States.

Ruzin A, Pastula ST, Levin-Sparenberg E, Jiang X, Fryzek J, Tovchigrechko A, Lu B, Qi Y, Liu H, Jin H, Yu L, Hackett J, Villafana T, Esser MT.

PLoS One. 2018 Jul 24;13(7):e0200319. doi: 10.1371/journal.pone.0200319. eCollection 2018.

6.

In Vitro Activity of LYS228, a Novel Monobactam Antibiotic, against Multidrug-Resistant Enterobacteriaceae.

Blais J, Lopez S, Li C, Ruzin A, Ranjitkar S, Dean CR, Leeds JA, Casarez A, Simmons RL, Reck F.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00552-18. doi: 10.1128/AAC.00552-18. Print 2018 Oct.

7.

Pseudomonas aeruginosa PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are Conserved Among Diverse Global Clinical Isolates.

Tabor DE, Oganesyan V, Keller AE, Yu L, McLaughlin RE, Song E, Warrener P, Rosenthal K, Esser M, Qi Y, Ruzin A, Stover CK, DiGiandomenico A.

J Infect Dis. 2018 Nov 5;218(12):1983-1994. doi: 10.1093/infdis/jiy438.

PMID:
30016475
8.

Characterisation of anti-alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against Staphylococcus aureus alpha toxin.

Ruzin A, Wu Y, Yu L, Yu XQ, Tabor DE, Mok H, Tkaczyk C, Jensen K, Bellamy T, Roskos L, Esser MT, Jafri HS.

Clin Transl Immunology. 2018 Jan 23;7(1):e1009. doi: 10.1002/cti2.1009. eCollection 2018.

9.

Prevalence of IgG and Neutralizing Antibodies against Staphylococcus aureus Alpha-Toxin in Healthy Human Subjects and Diverse Patient Populations.

Wu Y, Liu X, Akhgar A, Li JJ, Mok H, Sellman BR, Yu L, Roskos LK, Esser MT, Ruzin A.

Infect Immun. 2018 Feb 20;86(3). pii: e00671-17. doi: 10.1128/IAI.00671-17. Print 2018 Mar.

10.

In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.

Leeds JA, Sachdeva M, Mullin S, Barnes SW, Ruzin A.

J Antimicrob Chemother. 2014 Jan;69(1):41-4. doi: 10.1093/jac/dkt302. Epub 2013 Jul 25.

PMID:
23887866
11.

RT-PCR and statistical analyses of adeABC expression in clinical isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex.

Ruzin A, Immermann FW, Bradford PA.

Microb Drug Resist. 2010 Jun;16(2):87-9. doi: 10.1089/mdr.2009.0131.

PMID:
20438348
12.

In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections.

Petersen PJ, Ruzin A, Tuckman M, Jones CH.

Diagn Microbiol Infect Dis. 2010 Apr;66(4):407-18. doi: 10.1016/j.diagmicrobio.2009.11.009.

PMID:
20226331
13.

Resistance development profiling of piperacillin in combination with the novel {beta}-lactamase inhibitor BLI-489.

Ruzin A, Petersen PJ, Jones CH.

J Antimicrob Chemother. 2010 Feb;65(2):252-7. doi: 10.1093/jac/dkp435. Epub 2009 Dec 11.

PMID:
20008048
14.
15.
16.

Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae.

Ruzin A, Immermann FW, Bradford PA.

Antimicrob Agents Chemother. 2008 Sep;52(9):3430-2. doi: 10.1128/AAC.00591-08. Epub 2008 Jul 14.

17.

MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli.

Keeney D, Ruzin A, McAleese F, Murphy E, Bradford PA.

J Antimicrob Chemother. 2008 Jan;61(1):46-53. Epub 2007 Oct 29.

PMID:
17967850
19.
20.

Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Olson MW, Ruzin A, Feyfant E, Rush TS 3rd, O'Connell J, Bradford PA.

Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66.

21.

A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline.

McAleese F, Petersen P, Ruzin A, Dunman PM, Murphy E, Projan SJ, Bradford PA.

Antimicrob Agents Chemother. 2005 May;49(5):1865-71.

22.
23.

AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii.

Ruzin A, Keeney D, Bradford PA.

Antimicrob Agents Chemother. 2005 Feb;49(2):791-3.

24.

Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction.

Jennings LD, Foreman KW, Rush TS 3rd, Tsao DH, Mosyak L, Kincaid SL, Sukhdeo MN, Sutherland AG, Ding W, Kenny CH, Sabus CL, Liu H, Dushin EG, Moghazeh SL, Labthavikul P, Petersen PJ, Tuckman M, Haney SA, Ruzin AV.

Bioorg Med Chem. 2004 Oct 1;12(19):5115-31. Erratum in: Bioorg Med Chem. 2005 Oct 15;13(20):5884. Haney, Steven A [added].

PMID:
15351395
25.

Design and synthesis of indolo[2,3-a]quinolizin-7-one inhibitors of the ZipA-FtsZ interaction.

Jennings LD, Foreman KW, Rush TS 3rd, Tsao DH, Mosyak L, Li Y, Sukhdeo MN, Ding W, Dushin EG, Kenny CH, Moghazeh SL, Petersen PJ, Ruzin AV, Tuckman M, Sutherland AG.

Bioorg Med Chem Lett. 2004 Mar 22;14(6):1427-31.

PMID:
15006376
26.

Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteria.

Ruzin A, Singh G, Severin A, Yang Y, Dushin RG, Sutherland AG, Minnick A, Greenstein M, May MK, Shlaes DM, Bradford PA.

Antimicrob Agents Chemother. 2004 Mar;48(3):728-38.

27.

Structure-based design of carboxybiphenylindole inhibitors of the ZipA-FtsZ interaction.

Sutherland AG, Alvarez J, Ding W, Foreman KW, Kenny CH, Labthavikul P, Mosyak L, Petersen PJ, Rush TS 3rd, Ruzin A, Tsao DH, Wheless KL.

Org Biomol Chem. 2003 Dec 7;1(23):4138-40. Epub 2003 Oct 29.

PMID:
14685315
28.

Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus.

Ruzin A, Severin A, Moghazeh SL, Etienne J, Bradford PA, Projan SJ, Shlaes DM.

Biochim Biophys Acta. 2003 May 2;1621(2):117-21.

PMID:
12726988
29.

Further evidence that a cell wall precursor [C(55)-MurNAc-(peptide)-GlcNAc] serves as an acceptor in a sorting reaction.

Ruzin A, Severin A, Ritacco F, Tabei K, Singh G, Bradford PA, Siegel MM, Projan SJ, Shlaes DM.

J Bacteriol. 2002 Apr;184(8):2141-7.

30.

Molecular genetics of SaPI1--a mobile pathogenicity island in Staphylococcus aureus.

Ruzin A, Lindsay J, Novick RP.

Mol Microbiol. 2001 Jul;41(2):365-77.

31.

Pathogenicity and resistance islands of staphylococci.

Novick RP, Schlievert P, Ruzin A.

Microbes Infect. 2001 Jun;3(7):585-94. Review.

PMID:
11418332
33.

The gene for toxic shock toxin is carried by a family of mobile pathogenicity islands in Staphylococcus aureus.

Lindsay JA, Ruzin A, Ross HF, Kurepina N, Novick RP.

Mol Microbiol. 1998 Jul;29(2):527-43.

34.
35.

Supplemental Content

Support Center